Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial.
feasibility
oestrogen
pelvic organ prolapse
pilot
postmenopausal
recurrence
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
10 09 2020
10 09 2020
Historique:
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
27
3
2021
Statut:
epublish
Résumé
To evaluate the feasibility of a multicentre randomised controlled trial (RCT) comparing oestrogen treatment with no oestrogen supplementation in women undergoing pelvic organ prolapse (POP) surgery. A randomised, parallel, open, external pilot trial involving six UK urogynaecology centres (July 2015-August 2016). Postmenopausal women with POP opting for surgery, unless involving mesh or for recurrent POP in same compartment. Women were randomised (1:1) to preoperative and postoperative oestrogen or no treatment. Oestrogen treatment (oestradiol hemihydrate 10 μg vaginal pessaries) commenced 6 weeks prior to surgery (once daily for 2 weeks, twice weekly for 4 weeks) and twice weekly for 26 weeks from 6 weeks postsurgery. The main outcomes were assessment of eligibility and recruitment rates along with compliance and data completion. To obtain estimates for important aspects of the protocol to allow development of a definitive trial. 325 women seeking POP surgery were screened over 13 months and 157 (48%) were eligible. Of these, 100 (64%) were randomised, 50 to oestrogen and 50 to no oestrogen treatment, with 89 (44/45 respectively) ultimately having surgery. Of these, 89% (79/89) returned complete questionnaires at 6 months and 78% (32/41) reported good compliance with oestrogen. No serious adverse events were attributable to oestrogen use. A large multicentre RCT of oestrogen versus no treatment is feasible, as it is possible to randomise and follow up participants with high fidelity. Four predefined feasibility criteria were met. Compliance with treatment regimens is not a barrier. A larger trial is required to definitively address the role of perioperative oestrogen supplementation. ISRCTN46661996.
Identifiants
pubmed: 32912971
pii: bmjopen-2018-025141
doi: 10.1136/bmjopen-2018-025141
pmc: PMC7485245
doi:
Substances chimiques
Estrogens
0
Banques de données
ISRCTN
['ISRCTN46661996']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e025141Subventions
Organisme : Department of Health
ID : PB-PG-0213-30126
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: PML received sponsorship from Astellas, Contura and Pfizer to attend meetings.
Références
Lancet. 2017 Jan 28;389(10067):381-392
pubmed: 28010989
Int Urogynecol J Pelvic Floor Dysfunct. 2003 Aug;14(3):164-8; discussion 168
pubmed: 12955337
Maturitas. 1992 Dec;15(3):241-9
pubmed: 1465038
Am J Obstet Gynecol. 2005 Jul;193(1):103-13
pubmed: 16021067
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Maturitas. 1995 Jan;21(1):51-6
pubmed: 7731384
BMJ Open. 2018 Sep 25;8(9):e022233
pubmed: 30257847
Int Urogynecol J. 2010 May;21(5):523-8
pubmed: 20013110
Obstet Gynecol. 2005 Nov;106(5 Pt 1):953-63
pubmed: 16260512
Female Pelvic Med Reconstr Surg. 2013 Jan-Feb;19(1):34-9
pubmed: 23321657
Cochrane Database Syst Rev. 2010 Sep 08;(9):CD007063
pubmed: 20824855
Int Urogynecol J. 2016 Feb;27(2):165-94
pubmed: 26755051
Female Pelvic Med Reconstr Surg. 2012 Jul-Aug;18(4):211-5
pubmed: 22777369
Gynecol Obstet Invest. 1995;40(2):125-8
pubmed: 8575690